- Merck and Siemens signed a new MoU to enhance digital transformation in life sciences.
- The agreement includes using technology from Siemens' acquisition of Dotmatics in July 2025.
- Initial projects integrate Merck's AI tools with Siemens' Luma platform.
- Future initiatives will explore smarter data management and digital marketplaces.
Partnership Overview
Merck and Siemens have extended their strategic partnership through a new Memorandum of Understanding (MoU) aimed at accelerating digital transformation in the life sciences sector. This collaboration focuses on integrating digital and physical products to enhance drug discovery, development, and manufacturing processes.
Technological Integration
The agreement marks the first joint use of technology acquired by Siemens through its acquisition of Dotmatics, completed in July 2025. Initial pilot projects will involve integrating Merck's AI tools and digital applications with Siemens' Luma platform, providing scientists with a unified environment for data-driven decision-making.
Future Initiatives
Building on these initial projects, Merck and Siemens plan to pursue additional joint ventures, including the development of smarter data management tools and intuitive interfaces. The partnership will also explore digital marketplaces to offer streamlined access to complementary technologies and services.
Strategic Goals
The collaboration aims to set a new standard for digital transformation in life sciences, emphasizing the importance of digital innovation for future advancements. By connecting every step of drug development through a digital backbone, the partnership seeks to facilitate seamless data flow, faster insights, and quicker delivery of medications to patients.
